ORIENT PHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.6 TWD | -0.54% |
|
+2.60% | +38.00% |
| Apr. 15 | Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 512M 15.81M | Sales 2023 | 890M 27.49M | Capitalization | 4.46B 138M |
|---|---|---|---|---|---|
| Net income 2022 | -28M -865K | Net income 2023 | 22M 680K | EV / Sales 2022 | 8.44 x |
| Net Debt 2022 | 411M 12.69M | Net Debt 2023 | 604M 18.65M | EV / Sales 2023 | 5.69 x |
| P/E ratio 2022 |
-136
x | P/E ratio 2023 |
200
x | Employees | 173 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 15.26% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.54% | ||
| 1 week | +2.60% | ||
| Current month | +1.47% | ||
| 1 month | +9.52% | ||
| 3 months | +34.96% | ||
| 6 months | +34.31% | ||
| Current year | +38.00% |
1 week
26.45
28.10
1 month
25.0028.30
Current year
19.4528.60
1 year
18.5528.60
3 years
14.2528.60
5 years
12.5036.00
10 years
12.5092.29
| Managers | Title | Age | Since |
|---|---|---|---|
Chi Tai Chang
CEO | Chief Executive Officer | - | - |
Chia Ying Chen
DFI | Director of Finance/CFO | - | - |
Meng Lin Tsai
BRD | Director/Board Member | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Hung Tsai
CHM | Chairman | - | 08-01-14 |
Meng Lin Tsai
BRD | Director/Board Member | - | - |
Wei Chao Kao
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 27.6 | -0.54% | 130,402 |
| 24-06-12 | 27.75 | +3.35% | 201,452 |
| 24-06-11 | 26.85 | +0.19% | 128,249 |
| 24-06-07 | 26.8 | -0.37% | 19,664 |
| 24-06-06 | 26.9 | +0.37% | 61,410 |
End-of-day quote Taipei Exchange, June 12, 2024
More quotes
Orient Pharma Co., Ltd. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of western medicines. The Company's main products include hyperlipidemic drugs, diabetes drugs, cardiovascular drugs and drugs for musculoskeletal diseases. The Company is also involved in the original equipment manufacturer (OEM) manufacturing business and clinical trial business. The Company distributes its products in domestic market and to overseas markets, such as the United States, Ireland and mainland China.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +38.00% | 192M | |
| +51.54% | 781B | |
| -7.20% | 350B | |
| +18.67% | 330B | |
| +7.48% | 293B | |
| +16.91% | 248B | |
| +0.53% | 221B | |
| +11.06% | 217B | |
| +3.64% | 162B | |
| -3.96% | 157B |
- Stock Market
- Equities
- 4166 Stock
